Literature DB >> 34553266

Cereblon: promise and challenges for combating human diseases.

Hyoung Kyu Kim1, Jung Eun Seol1,2, Sang Woo Ahn2, Seungje Jeon1,3, Chul-Seung Park3, Jin Han4.   

Abstract

Cereblon (CRBN) is a substrate recognition protein in the E3-ligase ubiquitin complex. The binding target of CRBN varies according to tissues and cells, and the protein regulates various biological functions by regulating tissue-specific targets. As new endogenous targets of CRBN have been identified over the past decade, the physiological and pathological functions of CRBN and its potential as a therapeutic target in various diseases have greatly expanded. For this purpose, in this review article, we introduce the basic principle of the ubiquitin-proteasome system, the regulation of physiological/pathological functions related to the endogenous substrate of CRBN, and the discovery of immunomodulatory imide drug-mediated neo-substrates of CRBN. In addition, the development of CRBN-based proteolysis-targeting chimeras, which has been actively researched recently, and strategies for developing therapeutic agents using them are introduced. These recent updates on CRBN will be useful in the establishment of strategies for disease treatment and utilization of CRBNs in biomedical engineering and clinical medicine.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  CRBN; E3 ligase; IMiDs; PROTAC

Mesh:

Substances:

Year:  2021        PMID: 34553266     DOI: 10.1007/s00424-021-02624-0

Source DB:  PubMed          Journal:  Pflugers Arch        ISSN: 0031-6768            Impact factor:   3.657


  124 in total

1.  Discovery of Wogonin-based PROTACs against CDK9 and capable of achieving antitumor activity.

Authors:  Jinlei Bian; Jie Ren; Yongren Li; Jubo Wang; Xi Xu; Yifan Feng; Hui Tang; Yajing Wang; Zhiyu Li
Journal:  Bioorg Chem       Date:  2018-08-30       Impact factor: 5.275

2.  Selective CDK6 degradation mediated by cereblon, VHL, and novel IAP-recruiting PROTACs.

Authors:  Niall A Anderson; Jenni Cryan; Adil Ahmed; Han Dai; Grant A McGonagle; Christine Rozier; Andrew B Benowitz
Journal:  Bioorg Med Chem Lett       Date:  2020-03-10       Impact factor: 2.823

Review 3.  Targeting Histone Deacetylases in Diseases: Where Are We?

Authors:  Rosaria Benedetti; Mariarosaria Conte; Lucia Altucci
Journal:  Antioxid Redox Signal       Date:  2014-03-06       Impact factor: 8.401

Review 4.  Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia.

Authors:  Farrukh T Awan; Amy J Johnson; Rosa Lapalombella; Weihong Hu; Margaret Lucas; Beth Fischer; John C Byrd
Journal:  Leuk Lymphoma       Date:  2010-01

5.  Modulating PCAF/GCN5 Immune Cell Function through a PROTAC Approach.

Authors:  Zuni I Bassi; Martin C Fillmore; Afjal H Miah; Trevor D Chapman; Claire Maller; Emma J Roberts; Lauren C Davis; Darcy E Lewis; Nicholas W Galwey; Kirsty E Waddington; Valentino Parravicini; Abigail L Macmillan-Jones; Celine Gongora; Philip G Humphreys; Ian Churcher; Rab K Prinjha; David F Tough
Journal:  ACS Chem Biol       Date:  2018-09-18       Impact factor: 5.100

6.  p63 is a cereblon substrate involved in thalidomide teratogenicity.

Authors:  Tomoko Asatsuma-Okumura; Hideki Ando; Marco De Simone; Junichi Yamamoto; Tomomi Sato; Nobuyuki Shimizu; Kazuhide Asakawa; Yuki Yamaguchi; Takumi Ito; Luisa Guerrini; Hiroshi Handa
Journal:  Nat Chem Biol       Date:  2019-10-07       Impact factor: 15.040

Review 7.  Regulating the 20S proteasome ubiquitin-independent degradation pathway.

Authors:  Gili Ben-Nissan; Michal Sharon
Journal:  Biomolecules       Date:  2014-09-23

8.  Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4.

Authors:  C C Bjorklund; L Lu; J Kang; P R Hagner; C G Havens; M Amatangelo; M Wang; Y Ren; S Couto; M Breider; Y Ning; A K Gandhi; T O Daniel; R Chopra; A Klippel; A G Thakurta
Journal:  Blood Cancer J       Date:  2015-10-02       Impact factor: 11.037

9.  Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN.

Authors:  Chad C Bjorklund; Jian Kang; Michael Amatangelo; Ann Polonskaia; Mark Katz; Hsiling Chiu; Suzana Couto; Maria Wang; Yan Ren; Maria Ortiz; Fadi Towfic; J Erin Flynt; William Pierceall; Anjan Thakurta
Journal:  Leukemia       Date:  2019-11-12       Impact factor: 11.528

10.  PROTAC-mediated degradation reveals a non-catalytic function of AURORA-A kinase.

Authors:  Bikash Adhikari; Jelena Bozilovic; Mathias Diebold; Jessica Denise Schwarz; Julia Hofstetter; Martin Schröder; Marek Wanior; Ashwin Narain; Markus Vogt; Nevenka Dudvarski Stankovic; Apoorva Baluapuri; Lars Schönemann; Lorenz Eing; Pranjali Bhandare; Bernhard Kuster; Andreas Schlosser; Stephanie Heinzlmeir; Christoph Sotriffer; Stefan Knapp; Elmar Wolf
Journal:  Nat Chem Biol       Date:  2020-09-28       Impact factor: 15.040

View more
  1 in total

1.  3,6'- and 1,6'-Dithiopomalidomide Mitigate Ischemic Stroke in Rats and Blunt Inflammation.

Authors:  Yan-Rou Tsai; Dong Seok Kim; Shih-Chang Hsueh; Kai-Yun Chen; John Chung-Che Wu; Jia-Yi Wang; Yi-Syue Tsou; Inho Hwang; Yukyung Kim; Dayeon Gil; Eui Jung Jo; Baek-Soo Han; David Tweedie; Daniela Lecca; Michael T Scerba; Warren R Selman; Barry J Hoffer; Nigel H Greig; Yung-Hsiao Chiang
Journal:  Pharmaceutics       Date:  2022-04-27       Impact factor: 6.525

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.